33 withdrawn. 33 Phase 1, 14 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 33 | Withdrawn 33 |
| Phase 2 | 14 | Withdrawn 14 |
Follow Hypersensitivity: new trials by email Literature Review of Hypersensitivity trials Research Report on Hypersensitivity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1 Study of Cizutamig in IgE Mediated Diseases Cizutamig - IgE-Mediated Hypersensitivity, IgE Mediated Food Allergy | Phase 1 | Withdrawn | Candid Therapeutics | 2026-04-01 | 2026-07-22 | |
| A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Repeated-dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis BxC-I17e, Placebo - Atopic Dermatitis | Phase 1 | Withdrawn | Brexogen Inc. | 2024-05-01 | 2024-08-09 | |
| A Study of Topical BX005-A in Subjects With Moderate to Severe Atopic Dermatitis BX005-A, Placebo - Atopic Dermatitis | Phase 1 / Phase 2 | Withdrawn | BiomX, Inc. | 2022-05-01 | 2025-08-03 | |
| Safety and Pharmacokinetics of Orodispersible BT-11 in Active Eosinophilic Esophagitis BT-11 low, BT-11 high, Placebo - Eosinophilic Esophagitis | Phase 1 | Withdrawn | NImmune Biopharma | 2022-01-30 | 2023-06-07 | |
| Single and Multiple Doses of HA115 and Food Effect in Healthy Adult Volunteers HA115, Placebo - Asthma | Phase 1 | Withdrawn | Conjupro Biotherapeutics, Inc. | 2021-10-01 | 2021-09-08 | |
| Novel Treatment for Patients With Peanut Allergy: Intralymphatic Immunotherapy Peanut allergen - Food Allergy Peanut | Phase 1 / Phase 2 | Withdrawn | Scripps Health | 2021-03-01 | 2022-11-22 | |
| Late Phase Administration Anakinra as a Rescue Treatment for Inhaled Allergen Challenge-Induced Airway Inflammation Anakinra, Anakinra Matching Placebo, Dermatophagoides Farinae - Asthma | Phase 1 / Phase 2 | Withdrawn | University of North Carolina, Chapel Hill | 2020-09-01 | 2021-05-14 | |
| Anakinra as a Rescue Treatment for Allergic Inflammation Anakinra, Preservative-free 0.9% sodium chloride (Placebo), House dust mite allergen - Asthma, Allergic | Phase 1 / Phase 2 | Withdrawn | University of North Carolina, Chapel Hill | 2019-12-16 | 2022-06-08 | |
| Early Phase Administration of Anakinra as a Rescue Treatment for Inhaled Allergen Challenge-Induced Airway Inflammation Anakinra, Anakinra Matching Placebo, Dermatophagoides Farinae - Asthma | Phase 1 / Phase 2 | Withdrawn | University of North Carolina, Chapel Hill | 2019-08-09 | 2021-05-07 | |
| Airway Temperature Segmental Bronchoprovocation with Allergen (SBP-Ag) - Asthma | Phase 1 | Withdrawn | Lu Yuan Lee | 2018-11-08 | 2020-12-09 | |
| Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis Clobetasol 0.05% ointment, Placebo - Toxic Epidermal Necrolysis | Phase 1 / Phase 2 | Withdrawn | University of California, Davis | 2016-11-01 | 2019-08-09 | |
| Examination of Whether Host Preconditioning Modifies Short-term Transplant Survival Pre-Treatment with Dial liquid antibacterial soap, Control - Atopic Dermatitis, Eczema | Phase 1 | Withdrawn | University of California, San Diego | 2016-06-01 | 2020-11-05 | |
| Probiotic Supplementation in Breastfed Newborn Infants B. infantis, Placebo - Atopic Dermatitis, Food Allergies | Phase 1 | Withdrawn | Emanual Maverakis, MD | 2015-10-01 | 2019-11-15 | |
| Topical Infliximab in Autoimmune Eyes With Keratoprosthesis topical infliximab - Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis (Lyell) Syndrome | Phase 1 / Phase 2 | Withdrawn | James Chodosh, MD, MPH | 2014-11-01 | 2017-04-07 | |
| A Study in Patients With Moderate Asthma to Compare Pharmacokinetics and Pharmacodynamic Effects of Fluticasone Propionate and Salmeterol Delivered Via the ROTAHALER® Inhaler Relative to the DISKUS® Inhaler Fluticasone Propionate/Salmeterol Xinafoate DISKUS, Placebo to Match DISKUS, Fluticasone Propionate/Salmeterol Xinafoate ROTACAPS - Asthma | Phase 1 | Withdrawn | GlaxoSmithKline | 2014-10-01 | 2015-02-11 | |
| 0.005% Sodium Hypochlorite Final Rinse Solution in Atopic Dermatitis Sodium Hypochlorite - Atopic Dermatitis | Phase 1 | Withdrawn | Makati Medical Center | 2014-07-01 | 2015-10-20 | |
| Walnut Oral Immunotherapy for Tree Nut Allergy Walnut Protein Flour, Oat flour - Nut Hypersensitivities | Phase 1 / Phase 2 | Withdrawn | University of North Carolina, Chapel Hill | 2013-11-01 | 2016-06-17 | |
| A Single-Dose Study of MK-8351 in a Lung Allergen Challenge (MK-8351-003) Low-Dose MK-8351, High-Dose MK-8351, Placebo to MK-8351 - Asthma | Phase 1 | Withdrawn | Merck Sharp & Dohme LLC | 2013-09-01 | 2015-07-16 | |
| Effect of HSA or Saline Diluent on Immunotherapy Extract Stability as Determined by Graded ID Skin Tests saline with 1mg/ml Histamine base, diluent, saline with HSA--phenol - Allergic Rhinitis | Phase 1 / Phase 2 | Withdrawn | Bryan Martin, DO | 2013-03-01 | 2021-10-28 | |
| Predictors of Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis dexlansoprazole - Gastroesophageal Reflux Disease, Eosinophilic Esophagitis | Phase 1 / Phase 2 | Withdrawn | Mayo Clinic | 2012-03-01 | 2012-04-19 |
Showing 20 of 33. Sign in to see all of them.
Asthma (14) · Dermatitis, Atopic (8) · Rhinitis, Allergic (4) · Stevens-Johnson Syndrome (3) · Eosinophilic Esophagitis (2) · Food Hypersensitivity (2) · Hypersensitivity, Immediate (2) · Nut Hypersensitivity (2) · Peanut Hypersensitivity (2) · Behcet Syndrome (1) · Cryopyrin-Associated Periodic Syndromes (1) · Deglutition Disorders (1) · Dust Mite Allergy (1) · Eczema (1)
Immune System Diseases (33) · Hypersensitivity, Immediate (28) · Respiratory Hypersensitivity (17) · Respiratory Tract Diseases (17) · Bronchial Diseases (15) · Lung Diseases (14) · Lung Diseases, Obstructive (14) · Skin Diseases (12) · Skin and Connective Tissue Diseases (12) · Dermatitis (11) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (9) · Genetic Diseases, Inborn (9) · Skin Diseases, Genetic (9) · Skin Diseases, Eczematous (8)
Allergens (4) · Antigens, Dermatophagoides (3) · Interleukin 1 Receptor Antagonist Protein (3) · Infliximab (2) · Receptors, Interleukin-6 (2) · Sodium Chloride (2) · 3-(3-tert-butylsulfanyl-1-(4-(6-ethoxypyridin-3-yl)benzyl)-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl)-2,2-dimethylpropionic acid (1) · Anti-Allergic Agents (1) · Clobetasol (1) · Dexlansoprazole (1) · Dust (1) · Exercise (1) · Fluticasone (1) · Lovastatin (1) · Moxifloxacin (1)
University of North Carolina, Chapel Hill (5) · GlaxoSmithKline (2) · Allergy Therapeutics (1) · Amgen (1) · BiomX, Inc. (1) · Brexogen Inc. (1) · Bryan Martin, DO (1) · Candid Therapeutics (1) · Conjupro Biotherapeutics, Inc. (1) · Creabilis SA (1) · Emanual Maverakis, MD (1) · James Chodosh, MD, MPH (1) · Lu Yuan Lee (1) · Magna Pharmaceuticals, Inc. (1) · Makati Medical Center (1)
United States (13) · Canada (2) · Australia (1) · Germany (1) · Philippines (1) · United Kingdom (1)
Michelle Hernandez, MD (3) · Emanual Maverakis, MD (2) · James Chodosh, MD, MPH (2) · Blanca Camoretti-Mercado, Ph.D. (1) · Bryan Martin, DO (1) · Claes H Dohlman, MD, PhD (1) · David Peden, MD (1) · Donna Marie L. Sarrosa, MD, FPDS (1) · Edwin Kim, MD (1) · Jamaine Melisse L Cruz, MD (1) · Jeffrey A Alexander, MD (1) · Lu Yuan Lee, PhD (1)
R01HL135235 (3), U01AI123832 (1), UL1RR024999 (1)